Virtus LifeSci Biotech Clinical Trials ETF
14 hedge funds and large institutions have $9.72M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$540K | |
| 2 | +$363K | |
| 3 | +$234K | |
| 4 |
Morgan Stanley
New York
|
+$68.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$34.6K |
Top Sellers
| 1 | -$541K | |
| 2 | -$402K | |
| 3 | -$7.6K | |
| 4 |
GRP
Global Retirement Partners
San Rafael,
California
|
-$5K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$2.88K |